JPMorgan Chase & Co. Cuts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

JPMorgan Chase & Co. trimmed its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,643,755 shares of the company's stock after selling 357,642 shares during the quarter. JPMorgan Chase & Co. owned 1.29% of Taysha Gene Therapies worth $4,574,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Taysha Gene Therapies by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after buying an additional 641,305 shares in the last quarter. Geode Capital Management LLC lifted its position in Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock valued at $7,163,000 after purchasing an additional 682,273 shares during the last quarter. State Street Corp grew its position in Taysha Gene Therapies by 4.5% in the third quarter. State Street Corp now owns 3,469,068 shares of the company's stock worth $6,973,000 after acquiring an additional 150,647 shares in the last quarter. Quantum Private Wealth LLC lifted its stake in shares of Taysha Gene Therapies by 3.6% in the 4th quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company's stock valued at $1,375,000 after purchasing an additional 27,360 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after purchasing an additional 11,390 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Stock Up 2.2 %

Shares of Taysha Gene Therapies stock traded up $0.04 during trading on Wednesday, hitting $1.82. 3,023,169 shares of the stock traded hands, compared to its average volume of 2,156,813. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The stock's fifty day simple moving average is $1.54 and its 200 day simple moving average is $1.80. The firm has a market cap of $373.20 million, a P/E ratio of 2.89 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million during the quarter, compared to analysts' expectations of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, equities analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on TSHA shares. Chardan Capital reiterated a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.